Navigation Links


PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015

7/28/2015
INCLINE VILLAGE, Nev. , July 28, 2015  PDL BioPharma, Inc. (PDL, or the Company) (NASDAQ: PDLI ) today announced that the Company will release its second quarter 2015 financial results for the period ended June 30, 2015, on Wednesday, August 5, 2015, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss... [Comments]

Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions

7/28/2015
NEW YORK , July 28, 2015 People with a common form of hearing loss not helped by hearing aids achieved significant and sometimes profound improvements in their hearing and understanding of speech with hybrid cochlear implant devices, according to a new multicenter study led by specialists at NYU Langone Medical Center. In the study, described online ahead of print... [Comments]

XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique

7/28/2015
BILLERICA, Mass. , July 28, 2015 Seahorse Bioscience, the industry leader in tools for measuring cell metabolism, is the provider of XF Technology which is increasingly being adopted and utilized across all disease research areas. As the links between mitochondrial function and disease are increasingly revealed, exploration into cell metabolism is escalating rapidly. ... [Comments]

EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com

7/28/2015
London, UK (PRWEB) July 28, 2015 In terms of value, aluminium hydroxide production in EU27 reached more than EUR 1.022 billion in 2013; while production volume reached close to 1.84 million tonnes in the same year. As of 2013, Germany was the leading producing country with a share of 75.5% of... [Comments]

Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period

7/28/2015
DUBLIN , July 21, 2015 Research and Markets ( http://www.researchandmarkets.com/research/96s9kl/analysis_of_the ) has announced the addition of the "Analysis of the Global Flow Cytometry Market " report to their offering. Globally, flow cytometry remains a popular tool for research applications including immuno-phenotyping, cell proliferation, cancer, and stem cells. Bu... [Comments]

Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015

7/28/2015
DUBLIN , July 21, 2015 Research and Markets ( http://www.researchandmarkets.com/research/z54c4k/biomedical ) has announced the addition of the "Biomedical Refrigerators and Freezers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022" report to their offering. The global biomedical refrigerators and freezers market has been segmented ba... [Comments]

VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour

7/28/2015
Poway, CA (PRWEB) July 28, 2015 VetStem Biopharma will be offering weekly private guided tours of our new facility, followed by a live stem cell credentialing course to local area veterinarians. The tour and course will be given every Wednesday at 6pm to local interested veterinarians (3 R... [Comments]

Deerfield Launches $550 Million Healthcare Venture-Capital Fund

7/28/2015
NEW YORK , July 28, 2015 Deerfield Management Company, L.P. today announced the launch of the Deerfield Healthcare Innovations Fund, L.P., which will invest in groundbreaking advancements in science that may lead to therapeutic interventions in genetic diseases, cancer, and orphan diseases. The venture capital fund will also back new technologies that can transform how therape... [Comments]

Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock

7/28/2015
NEW YORK , July 28, 2015 Tauriga Sciences, Inc. (OTCQB:  TAUG) or ("Tauriga" or the "Company"), a diversified life sciences company, today announced that its stockholders approved an increase in the number of authorized shares of common stock of the Company from 1,000,000,000 to 2,500,000,000 at its Special Meeting of Stockholders held on July 27, 2015 at the Law Offices... [Comments]

Kerastem Receives Conditional Approval from FDA for Alopecia Trial

7/28/2015
SAN DIEGO , July 28, 2015  Kerastem Technologies announce that the Company has received notice of conditional approval from the U.S. FDA Center For Biologics Evaluation and Research (CBER) Office of Cellular, Tissue and Gene Therapies to conduct a clinical trial investigating the safety and feasibility of the Company's technology for the treatment of female and early male... [Comments]

[next]
(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... 2010) Today, the Association for Molecular Pathology (AMP) ... Genetics, Health and Society (SACHGS) meeting focused on whole ... and its incorporation into clinical practice, AMP raised ethical ... "In the next five years, the application of ...
... 2010) -- Atmospheric research often focuses on clouds, impact on weather ... with a base some 6,000 feet above earth. University of ... other end of the air column closer to homethe bottom of ... boundary layer. A report on his team,s work appears in a ...
... in the atmosphere rise, policy makers and scientists are ... with the greenhouse gas. One method ... otherwise known as carbon sequestration. CCS, a newly developing ... from the Earth,s atmosphere. Donald J. ...
Cached Biology News:AMP commends SACGHS whole genome sequencing focus, raises ethical questions and forms working group 2AMP commends SACGHS whole genome sequencing focus, raises ethical questions and forms working group 3
... antibody irreversibly crosslinked to protein G-agarose beads ... complex from heart mitochondria. Also included are ... control immunocapture. ,The pyruvate dehydrogenase complex (PDH) ... small amounts of tissue. This facilitates the ...
... cells permits studies of protein-protein interactions, protein ... transcription factor-mediated gene regulation. The most rapid ... specific protein in a mammalian cell is ... cell. ProteoJuice Protein Transfection Reagent is an ...
... BD FACSVantageTM SE flow cytometry system is ... laboratory. For over 25 years, BD cell ... are found in leading university, pharmaceutical, and ... To meet the research demands of today, ...
... is a microarray service provider ... academic researchers. We are a ... and we provide expression profiling ... arrays. Gene expression reports ...
Biology Products:
(Date:7/28/2015)... 2015 Tauriga Sciences, Inc. (OTCQB:  TAUG) or ... today announced that its stockholders approved an increase in ... the Company from 1,000,000,000 to 2,500,000,000 at its Special ... the Law Offices of Nixon Peabody LLP in Midtown ... were 480,655,929 shares of common stock represented either by ...
(Date:7/28/2015)... 28, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... has granted to German life sciences entrepreneurs with ... commercialization of biotechnology (collectively, the "Optionee"), an option ... tumor vaccine technology (the "Technology"), including AEZS-120, the ... is ready to enter a Phase 1 clinical ...
(Date:7/27/2015)... CHICAGO and FRANKLIN, Tenn. ... Inc. ("Capella"), a privately-owned  premier provider of health care ... companies in the U.S., today announced that its ... has signed a definitive agreement with Medical Properties ... the acquisition of Capella for $900 million in cash.  The ...
(Date:7/27/2015)... 27, 2015   Inocucor Technologies Inc ., ... accelerators for farmers, has received a notice of ... for its patent application to protect Inocucor consortia ... and enhance yields on farms and in greenhouses. ... live IN-M1 microbial consortium and its fermentation byproducts, ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) today ... of SYMLIN® (pramlintide acetate) injection in patients with type ... completed clinical studies. The data, which will be presented ... of the American Diabetes Association (ADA) in San Diego, ...
... June 24, 2011 /PRNewswire-iReach/ -- Harbour ... today the completion of a non-exclusive research and ... a global pharmaceutical company, to generate and develop ... chains(H2L2) using one of Harbour,s transgenic mouse antibody ...
... 24, 2011 ,   ... 2511) investigated the efficacy and safety of,the monoclonal ... This study showed that in patients with,severe AAV ... and,maintenance over a period of 18 months proved ...
Cached Biology Technology:Analysis Provides New Insights Into Use of SYMLIN® in Patients With Type 1 Diabetes Using Insulin Pumps 2Analysis Provides New Insights Into Use of SYMLIN® in Patients With Type 1 Diabetes Using Insulin Pumps 3Analysis Provides New Insights Into Use of SYMLIN® in Patients With Type 1 Diabetes Using Insulin Pumps 4Analysis Provides New Insights Into Use of SYMLIN® in Patients With Type 1 Diabetes Using Insulin Pumps 5Harbour Antibodies BV Signs Research and Licence Agreement With Lilly 2ERA-EDTA Congress 2011: Late Breaking Clinical Trials I 2